• Connect with RxStrategies at the 2020 Virtual Spring Hospital Pharmacy Conference

    RxStrategies’ Rhodie Smith will attend the 2020 Virtual Spring Hospital Pharmacy Conference. Providing educational sessions and meeting opportunities, the conference brings industry providers and suppliers together in a new virtual event format to learn, connect, and support each other.   Utilizing its virtual format, the conference will also include a Virtual Reverse Expo, which facilitates… Read more »

  • Clinical Insights: May 19, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval QinlockTM (ripretinib) Tablets – New Drug Approval – May 15, 2020 – The U.S. Food and Drug Administration approved QinlockTM (ripretinib) tablets as the first new drug specifically… Read more »

  • Clinical Insights: May 12, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval RetevmoTM (selpercatinib) Capsules – New Drug Approval – May 8, 2020 – The U.S. Food and Drug Administration approved RetevmoTM (selpercatinib) capsules to treat three types of tumors… Read more »

  • Clinical Insights: May 5, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Darzalex FasproTM (daratumumab and hyaluronidase-fihj) Injection – New Drug Approval – May 1, 2020 –  The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food… Read more »

  • Clinical Insights: April 30, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Ongentys® (opicapone) Capsules – New Drug Approval – April 27, 2020 – Neurocrine Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral… Read more »

  • Clinical Insights: April 24, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval TukysaTM (tucatinib) – New Drug Approval – April 17, 2020 – As part of Project Orbis, the U.S. Food and Drug Administration approved TukysaTM (tucatinib) in combination with chemotherapy… Read more »

  • Clinical Insights: April 16, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Koselugo® (selumetinib) – New Drug Approval – April 10, 2020 – The U.S. Food and Drug Administration approved Koselugo® (selumetinib) for the treatment of pediatric patients, 2 years… Read more »

  • Clinical Insights: April 9, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Sevenfact® (coagulation factor VIIa [recombinant]-jncw) – New Drug Approval – April 1, 2020 – The U.S. Food and Drug Administration approved Sevenfact® [coagulation factor VIIa (recombinant)-jncw] for the treatment and… Read more »

  • Clinical Insights: April 1, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Zeposia® (ozanimod) Capsules – New Drug Approval – March 26, 2020 – Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved Zeposia® (ozanimod) 0.92… Read more »

  • Clinical Insights: March 24, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Isturisa® (osilodrostat) Tablets – New Orphan Drug Approval – March 6, 2020 – The U.S. Food and Drug Administration announced the approval of Isturisa® (osilodrostat)… Read more »